Table 1.

Demographic and disease characteristics of patients grouped according to the clinical response to re-RT.

Characteristics			Responding (n = 24)				Non-responding (n = 7)				All patients (n = 31)
Patient characteristics
Gender
		Male	11			46%	3			43%	14			45%
		Female	13			54%	4			57%	17			56%
Age (years)
		Median	8				6				6
		Range	3 to 16				2 to 13				2 to 16
		≤6 yo	11			46%	5			71%	16			52%
		>6 yo	13			54%	2			29%	15			48%
PFS (days)
		Median	245,5				236				245
		Range	112 to 374				168 to 952				112 to 952
Interval RT to re-RT (days)
		Median	225.5				209				217
		Range	103 to 363				112 to 930				103 to 930
Survival time (days)
		Median	150				90				146
		Range	67 to 325				21 to 297				21 to 325
Treatment characteristics
Second line treatment
		RT	12			50%	4			43%	16			52%
		RT + chemo	12			50%	3			57%	15			48%
re-RT dose given (Gy)
		Median	20				19,8				20
		Range	18 to 30				18 to 30				18 to 30
		< 20 Gy	10			42%	4			57%	14			45%
		≥ 20 Gy	14			58%	3			43%	17			55%

PFS, progression-free survival. yo, years old. Interval RT to re-RT, interval of time from the last day of RT and the first day of re-RT. Survival time, survival from start of re-RT to death/last follow-up. Chemo, chemotherapy (part of the second-line treatment in addition to re-RT: nimotuzumab–vinorelbine based, n = 9; etoposide, n = 1; sirolimus, n = 2; valproic acid + celecoxib, n = 1; valproic acid + temsirolimus + irinotecan, n = 1; bevacizumab, n = 1).